Advertisement

Organisation › Details
Mablink Bioscience SAS
Mablink Bioscience is a French-based biopharmaceutical company which has developed PSARlink™, an innovative and patented hydrophilic drug-linker technology that brings dramatically improved pharmacological properties to antibody-drug conjugates. Mablink Bioscience develops its own pipeline of ADC targeting several cancers with high unmet medical needs. *
![]() |
Start | 2018-12-05 established |
Group | Eli Lilly (Group) | |
![]() |
Industry | PSARlink™ drug-linkers |
Industry 2 | antibody-drug conjugate (ADC) | |
![]() |
Person | Lafay, Jean-Guillaume (Mablink Bioscience 202104 CEO + Co-Founder) |
![]() |
Region | Lyon |
Country | France | |
Street | 60 avenue Rockefeller Immeuble Adenine | |
City | 69008 Lyon | |
Tel | +33-4-8776-8028 | |
Address record changed: 2022-10-18 | ||
Basic data | Employees | n. a. |
* Document for »About Section«: Mablink Bioscience SAS. (4/27/21). "Press Release: Mablink Bioscience, the Next Generation ADC Company, Raises €4 Million from a Syndicate of Private Investors". Lyon. | ||
Record changed: 2024-03-30 |
Advertisement

More documents for Eli Lilly (Group)
- [1] NanoSyrinx Ltd.. (9/10/24). "Press Release: NanoSyrinx Closes £10 Million GBP Financing and Appoints Dr. Edwin Moses as Chairman". Coventry....
- [2] Qiagen N.V.. (9/4/24). "Press Release: Qiagen and Lilly Collaborate to Support Development of a QIAstat-Dx IVD Panel that Identifies Patients at Risk for Developing Alzheimer’s disease". Venlo....
- [3] Haya Therapeutics SA. (9/4/24). "Press Release: Haya Therapeutics Announces Collaboration with Lilly to Discover Novel Regulatory Genome Targets for Obesity and Related Metabolic Conditions Using Proprietary RNA Platform". Lausanne & San Diego, CA....
- [4] Kurma Partners. (5/2/24). "Press Release: Kurma Partners Announces the Promotion of Hadrien Bouchez to the Position of Partner". Paris....
- [5] Eli Lilly and Company. (12/27/23). "Press Release: Lilly Completes Acquisition of Point Biopharma". Indianapolis, IN....
- [6] Eli Lilly and Company. (11/17/23). "Press Release: Lilly to Expand Injectable Manufacturing Capacity with Planned $2.5 Billion Site in Germany". Indianapolis, IN....
- [7] Eli Lilly and Company. (11/17/23). "Press Release: Lilly Extends Tender Offer to Acquire Point Biopharma to Dec. 1, 2023". Indianapolis, IN....
- [8] Mablink Bioscience SAS. (10/18/23). "Press Release: Mablink Bioscience Enters an Agreement to be Acquired by Lilly". Lyon....
- [9] Eli Lilly and Company. (10/3/23). "Press Release: Lilly to Acquire Point Biopharma to Expand Oncology Capabilities into Next-Generation Radioligand Therapies". Indianapolis, IN....
- [10] Eckert & Ziegler AG. (9/25/23). "Press Release: Eckert & Ziegler Signs Strategically Important Agreement for the Supply of Lutetium-177 with POINT Biopharma". Berlin....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement

» top